296 related articles for article (PubMed ID: 28739492)
1. Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
Viscogliosi G; Chiriac IM; Ettorre E
J Am Med Dir Assoc; 2017 Sep; 18(9):799-802. PubMed ID: 28739492
[TBL] [Abstract][Full Text] [Related]
2. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
[TBL] [Abstract][Full Text] [Related]
3. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
4. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
Peters ME; Vaidya V; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Avramopoulos D;
J Geriatr Psychiatry Neurol; 2016 Mar; 29(2):59-64. PubMed ID: 26303700
[TBL] [Abstract][Full Text] [Related]
5. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.
Zhong KX; Tariot PN; Mintzer J; Minkwitz MC; Devine NA
Curr Alzheimer Res; 2007 Feb; 4(1):81-93. PubMed ID: 17316169
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Citalopram Compared With Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
Viscogliosi G; Chiriac IM; Ettorre E
J Am Med Dir Assoc; 2018 Jan; 19(1):89-90. PubMed ID: 29153751
[No Abstract] [Full Text] [Related]
7. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
[TBL] [Abstract][Full Text] [Related]
8. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
[TBL] [Abstract][Full Text] [Related]
9. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
Clark WS; Street JS; Feldman PD; Breier A
J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
13. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
Ho T; Pollock BG; Mulsant BH; Schantz O; Devanand DP; Mintzer JE; Porsteinsson AP; Schneider LS; Weintraub D; Yesavage J; Drye LT; Munro CA; Shade DM; Lyketsos C; Bies R
Br J Clin Pharmacol; 2016 Sep; 82(3):784-92. PubMed ID: 27145364
[TBL] [Abstract][Full Text] [Related]
14. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Drye LT; Spragg D; Devanand DP; Frangakis C; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
PLoS One; 2014; 9(6):e98426. PubMed ID: 24914549
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
[TBL] [Abstract][Full Text] [Related]
17. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
[TBL] [Abstract][Full Text] [Related]
18. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
Weintraub D; Drye LT; Porsteinsson AP; Rosenberg PB; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Yesavage J; Lyketsos CG;
Am J Geriatr Psychiatry; 2015 Nov; 23(11):1127-33. PubMed ID: 26238225
[TBL] [Abstract][Full Text] [Related]
19. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
Tariot PN; Raman R; Jakimovich L; Schneider L; Porsteinsson A; Thomas R; Mintzer J; Brenner R; Schafer K; Thal L; ;
Am J Geriatr Psychiatry; 2005 Nov; 13(11):942-9. PubMed ID: 16286437
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe?
Angelini A; Bendini C; Neviani F; Neri M
Arch Gerontol Geriatr; 2007; 44 Suppl 1():35-43. PubMed ID: 17317431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
